Novartis Aktie
Kursziele der Novartis-Aktie in CHF
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Goldman Sachs Group Inc. | 110,00 CHF | -8,18% | 22.09.2026 | |
| Deutsche Bank AG | 120,00 CHF | +0,17% | 18.09.2026 | |
| UBS AG | - | - | 17.09.2026 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 105,00 CHF | -12,35% | 11.09.2026 | |
| RBC Capital Markets | 120,00 CHF | +0,17% | 09.09.2026 | |
| Jefferies & Company Inc. | 110,00 CHF | -8,18% | 08.09.2026 | |
| Barclays Capital | 130,00 CHF | +8,51% | 08.09.2026 | |
| JP Morgan Chase & Co. | 135,00 CHF | +12,69% | 10.08.2026 | |
| DZ BANK | - | - | 22.07.2026 | |
| Bernstein Research | 132,84 CHF | +10,88% | 22.07.2026 |
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 9 | 1 | 0 | 158,22 GBP | - |
| Bayer | 7 | 2 | 0 | 56,56 EUR | +13,53% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 1 | 2 | 0 | 5,70 EUR | +106,22% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 3 | 5 | 2 | 18,62 GBP | - |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 3 | 5 | 0 | 147,57 EUR | +8,47% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 1 | 8 | 1 | 120,35 CHF | +0,46% |
| Pfizer Inc. | 2 | 5 | 1 | 27,14 USD | -5,34% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Roche Holding AG Inhaber-Partizipationsschein | 2 | 2 | 0 | - | - |
| Sanofi S.A. | 5 | 5 | 0 | 93,53 EUR | +30,88% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |